Moody Aldrich Partners LLC Sells 23,825 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Moody Aldrich Partners LLC decreased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 19.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 99,684 shares of the company’s stock after selling 23,825 shares during the period. Moody Aldrich Partners LLC’s holdings in BridgeBio Pharma were worth $2,735,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Atomi Financial Group Inc. acquired a new stake in shares of BridgeBio Pharma in the 4th quarter valued at $392,000. Moss Adams Wealth Advisors LLC bought a new stake in shares of BridgeBio Pharma in the 4th quarter valued at about $208,000. Avanza Fonder AB bought a new stake in shares of BridgeBio Pharma in the 4th quarter valued at about $181,000. Principal Financial Group Inc. grew its position in shares of BridgeBio Pharma by 1.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company’s stock valued at $29,155,000 after purchasing an additional 19,978 shares during the period. Finally, Exome Asset Management LLC grew its position in shares of BridgeBio Pharma by 167.4% in the 3rd quarter. Exome Asset Management LLC now owns 211,000 shares of the company’s stock valued at $5,372,000 after purchasing an additional 132,093 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on BBIO shares. Oppenheimer began coverage on BridgeBio Pharma in a research report on Thursday, October 3rd. They set a “market perform” rating for the company. Scotiabank increased their price target on BridgeBio Pharma from $45.00 to $48.00 and gave the company a “sector outperform” rating in a research note on Monday, November 25th. Bank of America increased their price objective on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. Evercore ISI increased their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, December 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $49.00 target price on shares of BridgeBio Pharma in a report on Monday, December 16th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $48.08.

BridgeBio Pharma Trading Down 1.0 %

BBIO opened at $36.31 on Wednesday. The stock has a 50-day moving average price of $29.09 and a 200-day moving average price of $26.97. BridgeBio Pharma, Inc. has a 12-month low of $21.62 and a 12-month high of $41.04. The stock has a market capitalization of $6.86 billion, a P/E ratio of -15.07 and a beta of 1.05.

Insider Transactions at BridgeBio Pharma

In related news, CFO Brian C. Stephenson sold 4,156 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total transaction of $93,135.96. Following the completion of the sale, the chief financial officer now directly owns 93,758 shares in the company, valued at $2,101,116.78. This represents a 4.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Neil Kumar sold 27,389 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total value of $613,787.49. Following the sale, the chief executive officer now owns 4,897,443 shares of the company’s stock, valued at $109,751,697.63. This represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 24.66% of the company’s stock.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.